Dayvigo (Lemborexant) Cost in Ohio: Prices, Insurance, and Savings in 2026

What Dayvigo Actually Costs at Ohio Pharmacies

The sticker price and the price you pay are rarely the same number. Eisai lists Dayvigo at $320 for a 30-tablet supply, but competitive discounting among Ohio retail pharmacies has pushed the average cash-pay price to roughly $85 per month in 2026.

Pricing varies by pharmacy and zip code. A CVS in Columbus may charge differently than an independent pharmacy in Akron, so checking multiple locations before filling is worth the extra five minutes. Discount platforms such as GoodRx or RxSaver can pull real-time quotes from pharmacies within a given Ohio area code.

Dayvigo is dispensed as a 5 mg or 10 mg oral tablet taken once at bedtime. The FDA-approved prescribing information recommends starting at 5 mg, with an increase to 10 mg based on clinical response and tolerability. Both strengths carry similar pricing at most pharmacies, so a dose increase does not automatically double the monthly bill.

For patients without insurance, the cash price near $85 represents a significant discount from the list price. That gap exists because pharmacy benefit managers negotiate rebates that reduce the acquisition cost for retail chains. The patient still pays more than insured counterparts in most cases, but the difference is smaller than the list price suggests.

Ohio Medicaid and Dayvigo Coverage

Ohio Medicaid does not cover Dayvigo for primary insomnia as of 2026. The Ohio Department of Medicaid formulary restricts the drug to type 2 diabetes-related indications, which effectively blocks coverage for the vast majority of patients seeking it for sleep.

This is not unusual among state Medicaid programs. Dual orexin receptor antagonists (DORAs) remain a newer and more expensive drug class compared to generic alternatives like trazodone, doxepin (at the 3 mg or 6 mg Silenor dose), or generic zolpidem. Medicaid preferred drug lists tend to require failure of at least one or two generic options before considering branded sleep agents, and Ohio's current list does not include a prior authorization pathway for Dayvigo in insomnia at all.

Patients enrolled in Ohio Medicaid managed care plans (such as CareSource, Molina, Buckeye, or UnitedHealthcare Community Plan) should verify formulary status directly with their plan. Managed care organizations sometimes maintain supplemental formularies that differ slightly from the fee-for-service list. A prescriber can also submit a prior authorization request citing clinical necessity, though approval rates for non-formulary branded sleep medications remain low.

The SUNRISE-1 trial (N=1,006) demonstrated that lemborexant 5 mg and 10 mg significantly improved sleep onset latency and wake-after-sleep-onset compared to placebo over 30 nights in adults aged 55 and older with insomnia disorder (Rosenberg et al., JAMA Netw Open, 2019) [1]. Despite that evidence, payer decisions in Ohio still favor generics for first-line treatment.

Commercial Insurance Coverage in Ohio

Most major commercial insurers in Ohio place Dayvigo on a Tier 3 (preferred brand) or Tier 4 (non-preferred brand) formulary position. Plans from Anthem Blue Cross Blue Shield, Medical Mutual of Ohio, SummaCare, and UnitedHealthcare each have their own formulary rules, but the pattern is consistent: prior authorization is typically required, and patients usually need documented failure of at least one generic hypnotic.

Prior authorization criteria commonly include:

• Diagnosis of insomnia disorder (ICD-10 G47.00)
• Trial and failure of, or contraindication to, zolpidem or another generic agent
• Prescriber attestation that non-pharmacologic interventions (such as cognitive behavioral therapy for insomnia, or CBT-I) have been considered

Co-pays under commercial plans with prior authorization approval range from $30 to $75 per month at Tier 3, or $75 to $150 at Tier 4. The Eisai co-pay savings card can offset some or all of that amount for eligible patients (details below).

The American Academy of Sleep Medicine's 2017 clinical practice guideline recommends CBT-I as first-line therapy for chronic insomnia, with pharmacotherapy reserved for patients who do not respond adequately or who need short-term bridging (Sateia et al., J Clin Sleep Med, 2017) [2]. Ohio insurers frequently reference these guidelines when structuring step-therapy requirements.

How the Eisai Savings Card Works in Ohio

Eisai offers a manufacturer co-pay assistance program for Dayvigo that Ohio residents with commercial insurance can use. The card is not available to patients covered by Medicare, Medicaid, Tricare, or other government-funded programs.

Eligible patients may pay as little as $0 out of pocket per fill, depending on the terms of the current program year. The card typically covers the difference between the patient's co-pay and a set maximum benefit per month or per year. Eisai updates the program terms annually, so confirming the current benefit cap before each refill is a practical step.

To activate the card, patients register through the Dayvigo website or receive a voucher from their prescriber's office. The pharmacy processes the card as a secondary payer after the primary insurance adjudicates. Processing takes no extra time at the pharmacy counter once the card is on file.

One limitation: the savings card does not apply to the deductible phase of high-deductible health plans in the same way a standard co-pay card does. Some plans use accumulator adjustment programs that prevent manufacturer co-pay assistance from counting toward the patient's annual deductible or out-of-pocket maximum. Ohio has not passed accumulator adjustment legislation as of 2026, so plan terms govern.

Compounded Lemborexant in Ohio: Legality and Access

Compounded lemborexant is available in Ohio through licensed 503A compounding pharmacies. Under federal law (the Drug Quality and Security Act of 2013), 503A pharmacies may compound medications based on a valid patient-specific prescription when a prescriber determines that a commercially available product does not meet the patient's needs (FDA, Drug Quality and Security Act) [3].

Ohio law aligns with federal compounding regulations. The Ohio Board of Pharmacy licenses and inspects 503A pharmacies within the state. A compounded version of lemborexant might be prescribed when a patient requires a non-standard dose, cannot swallow tablets, or needs an alternative formulation such as a sublingual troche or suspension.

Cost is a motivating factor for many patients. Compounded lemborexant from a 503A pharmacy can cost significantly less than the branded product, with some Ohio compounding pharmacies pricing it near $0 above their standard compounding fee for existing patients. Prices vary widely, though, so obtaining quotes from two or three compounding pharmacies is reasonable.

Patients should confirm that the compounding pharmacy holds a current Ohio Board of Pharmacy license and uses USP-compliant processes. The prescriber must write a patient-specific prescription; 503A pharmacies cannot compound and stockpile medications without individual prescriptions.

Dr. Andrew Krystal, professor of psychiatry and behavioral sciences at the University of California, San Francisco, has noted: "The dual orexin receptor antagonist class represents a mechanistically distinct approach to insomnia that targets the wake-promotion system rather than broadly suppressing CNS activity" (Krystal et al., Sleep Med Rev, 2020) [4]. That pharmacologic distinction partly explains prescriber interest in DORAs for patients who have not responded to GABA-modulating agents.

Getting Dayvigo via Telehealth in Ohio

Ohio permits telehealth prescribing of Dayvigo. The Ohio State Medical Board allows physicians and other authorized prescribers to evaluate patients and prescribe Schedule IV controlled substances (Dayvigo's DEA classification) via synchronous audio-video telehealth visits.

A telehealth consultation does not change the drug's cost, but it does expand access for patients in rural Ohio counties where sleep medicine specialists are scarce. Ohio has 88 counties, and board-certified sleep specialists practice predominantly in the metro areas of Columbus, Cleveland, Cincinnati, and Toledo. Telehealth closes that gap.

The prescriber must document a clinical evaluation sufficient to establish the insomnia diagnosis and rule out contributing conditions such as obstructive sleep apnea, restless legs syndrome, or circadian rhythm disorders. An initial in-person visit is not required under current Ohio telehealth rules for Schedule IV prescriptions, but some insurance plans impose their own requirements.

HealthRX offers telehealth evaluations for insomnia in Ohio. Patients who receive a Dayvigo prescription through telehealth fill it at any Ohio pharmacy, whether retail or compounding, using whichever pricing pathway works best for their coverage situation.

Comparing Dayvigo to Other Insomnia Medications in Ohio

Choosing a sleep medication involves balancing efficacy, side-effect profile, and cost. Ohio patients considering Dayvigo should understand where it fits relative to alternatives.

Generic zolpidem (immediate-release) costs $5 to $15 per month at most Ohio pharmacies and is covered by virtually all insurance plans without prior authorization. It works through GABA-A receptor modulation and has well-documented risks of complex sleep behaviors, next-morning impairment, and tolerance with long-term use (FDA Drug Safety Communication, 2013) [5].

Suvorexant (Belsomra), the other FDA-approved DORA, carries a list price comparable to Dayvigo. It was the first orexin antagonist approved (2014) and has a longer half-life than lemborexant, which may increase next-day residual sleepiness at higher doses.

Generic doxepin 3 mg and 6 mg (the low-dose formulation approved for sleep-maintenance insomnia) costs under $20 per month and is well-tolerated in older adults. The Endocrine Society and the American Geriatrics Society have both flagged benzodiazepine receptor agonists as potentially inappropriate in older adults, making DORAs and low-dose doxepin preferred options in that population (American Geriatrics Society, J Am Geriatr Soc, 2019) [6].

In SUNRISE-2, the 12-month extension study, lemborexant demonstrated sustained efficacy without evidence of rebound insomnia or withdrawal upon discontinuation (N=949) (Kärppä et al., Sleep, 2020) [7]. That long-term safety profile is a differentiator. Zolpidem lacks comparable 12-month randomized data, and clinical guidelines recommend limiting its use to the shortest effective duration.

Practical Steps to Lower Your Dayvigo Cost in Ohio

Ohio residents can take several concrete actions to reduce out-of-pocket spending on Dayvigo.

First, check whether your insurance covers it and what tier it occupies. Call the number on the back of your insurance card and ask for formulary status and prior authorization requirements. If prior authorization is needed, your prescriber's office handles the paperwork, but you can accelerate the process by confirming your insurer's specific step-therapy criteria in advance.

Second, register for the Eisai savings card if you have commercial insurance. Even a Tier 3 co-pay of $50 may be reduced to $0.

Third, compare cash prices across Ohio pharmacies using a discount tool if you are uninsured. The difference between the highest and lowest cash price in a single metro area can exceed $100.

Fourth, ask your prescriber whether a compounded formulation from a licensed 503A pharmacy is appropriate for your clinical situation. If a non-standard dose or formulation is genuinely needed, compounded lemborexant may cost less than the branded tablet.

Dr. Michael Thorpy, director of the Sleep-Wake Disorders Center at Montefiore Medical Center, has stated: "Cost remains one of the most significant barriers to patients accessing newer insomnia therapies, even when those therapies offer a better safety profile than older options" (Thorpy, Sleep Med Clin, 2022) [8]. That observation applies directly to the Ohio market, where Medicaid exclusion and high commercial co-pays push patients toward less expensive but pharmacologically older alternatives.

Fifth, if you are a Medicare Part D beneficiary, check whether your specific plan covers Dayvigo. Coverage varies by plan. The Medicare Plan Finder tool at medicare.gov allows you to search by drug name and zip code.

Patients who exhaust all other options may qualify for Eisai's patient assistance program, which provides Dayvigo at no cost to patients who meet income eligibility criteria (typically at or below 400% of the federal poverty level). Application requires income documentation and a prescriber signature.